A Phase 1 Study Evaluating the Effects of ARO-RAGE Injection for Subcutaneous Administration in Healthy Subjects
Latest Information Update: 20 Feb 2025
At a glance
- Drugs ARO-RAGE (Primary)
- Indications Asthma
- Focus Adverse reactions
- Sponsors Arrowhead Pharmaceuticals
Most Recent Events
- 28 Mar 2024 Status changed from recruiting to completed.
- 30 Jan 2024 Planned End Date changed from 1 Dec 2023 to 1 Feb 2024.
- 30 Jan 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Feb 2024.